Aquestive Therapeutics, Inc.
$4.24
0%
2026-04-21 05:22:00
www.aquestive.com
NGM: AQST
Explore Aquestive Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$527.23 M
Current Price
$4.24
52W High / Low
$7.55 / $2.12
Stock P/E
—
Book Value
$-0.28
Dividend Yield
—
ROCE
-62.98%
ROE
178.61%
Face Value
—
EPS
$-0.78
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
147
Beta
1.53
Debt / Equity
-1.26
Current Ratio
3.13
Quick Ratio
3.01
Forward P/E
-7.03
Price / Sales
11.18
Enterprise Value
$419.26 M
EV / EBITDA
-5.95
EV / Revenue
9.41
Rating
Strong Buy
Target Price
$8.89
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 2. | Eton Pharmaceuticals, Inc. | $25.28 | — | $683.2 M | — | -1.57% | -18.19% | $27.29 / $13.09 | $0.97 |
| 3. | Indivior Pharmaceuticals, Inc. | $32.42 | 31.62 | $3.95 B | — | 92.33% | -96.33% | $38 / $8.69 | $-0.78 |
| 4. | Apimeds Pharmaceuticals US, Inc. | $1.88 | — | $23.64 M | — | 126.09% | 209.61% | $40.31 / $1.61 | $0.65 |
| 5. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 6. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 7. | Prestige Consumer Healthcare Inc. | $58.68 | 14.89 | $2.78 B | — | 10.6% | 10.31% | $89.37 / $51.24 | $38.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 13.02 M | 12.81 M | 10 M | 8.72 M | 11.87 M | — |
| Operating Profit | -28.84 M | -11.48 M | -11.37 M | -19.36 M | -13.58 M | — |
| Net Profit | -31.86 M | -15.45 M | -13.55 M | -22.93 M | -17.05 M | — |
| EPS in Rs | -0.26 | -0.13 | -0.11 | -0.19 | -0.14 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 44.55 M | 57.56 M | 50.58 M | 47.68 M |
| Operating Profit | -71.05 M | -30.77 M | -15.1 M | -42.07 M |
| Net Profit | -83.78 M | -44.14 M | -7.87 M | -54.41 M |
| EPS in Rs | -0.69 | -0.36 | -0.06 | -0.45 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 160.43 M | 101.42 M | 57.42 M | 57.07 M |
| Total Liabilities | 194.09 M | 161.58 M | 163.91 M | 175.62 M |
| Equity | -33.66 M | -60.16 M | -106.49 M | -118.55 M |
| Current Assets | 149.27 M | 88.22 M | 40.97 M | 39.89 M |
| Current Liabilities | 47.61 M | 18.86 M | 18.31 M | 39.53 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -52.43 M | -35.76 M | -6.38 M | -9.82 M |
| Investing CF | -0.56 M | -0.16 M | -0.99 M | -2.52 M |
| Financing CF | 102.62 M | 83.59 M | 3.97 M | 11.59 M |
| Free CF | -52.99 M | -35.92 M | -7.38 M | -12.34 M |
| Capex | -0.56 M | -0.16 M | -0.99 M | -2.52 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 13.8% | 6.09% | — | — |
| Earnings Growth % | -460.83% | 85.54% | — | — |
| Profit Margin % | -76.68% | -15.56% | -114.11% | — |
| Operating Margin % | -53.46% | -29.86% | -88.23% | — |
| Gross Margin % | 68.95% | 58.82% | 59.34% | — |
| EBITDA Margin % | -46.24% | 2.34% | -83.01% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.